Stocks · News reference
Agenus Announces Registrational Phase 3 ROBBIN Trial Of Neoadjuvant BOT+BAL In High-Risk MSS Colon Cancer, With Initiation And First Patient Dosing Expected In Q1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
8-K filing — AGENUS INC (AGEN)
Filed: 2026-08-18 AccNo: 0001193125-26-355559 Size: 146 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities